You are here

Home » Content

Gastrointestinal ve Pankreatik Nöroendokrin Tümörlerde Prognostik Parametreler

The Prognostic Parameters in Gastrointestinal and Pancreatic Neuroendocrine Tumors

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2012
DOI: 
http://dx.doi.org/10.5505/abantmedj.2012.02411

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: In this study, we aimed that to find the differences in prognostic parameters as diameter, mitosis, necrosis, angiolymphatic invasion, perinoral invasion and lymph node metastasis of gastroenteropancreatic neuroendocrine tumor (GEPNET) cases which were classified by WHO. Method: Between 2001-2009 in Istanbul Educational And Research Hospital Hospital Pathology Department 41 GEPNET cases were searched according to age, gender, localization, diameter, mitosis, necrosis, angiolymphatic invasion, perinoral invasion and lymph node metastasis. Results: Tumor diameter was 0,76±0,78 cm in benign group and 2,82±2,86 cm in malign group (p=0.006). There was not significant differences between well differentiated neuroendocrine tumor and well differentiated neuroendocrine carcinomas for number of mitosis(p>0,05), but poorly differantiated neuroendocrine carcinomas had significantly higher number of mitosis than the others (p<0.001). Conclusion: Finally in our study, statistically meaningfull results were found in benign and malignant groups according to tumor diameter. Tumor diameter is not always a dependable parameter in GEPNET. Mitosis were low in well differentiated carcinomas as in benign groups. High mitotic number are related to poor prognosis but low proliferation activity is not associated with a benign behavior.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmada, WHO’ya göre klasifiye edilen gastroenteropankreatik nöroendokrin tümörler(GEPNET) olgularında; çap, mitoz, nekroz, anjiyolenfatik invazyon, perinöral invazyon ve lenf nodu metastazı gibi prognostik parametreler açısından tümör grupları arasındaki farklılıkların ortaya konulması amaçlanmıştır. Yöntem: 2001-2009 yılları arasında İstanbul Eğitim ve Araştırma Hastanesi Patoloji Bölümünde tanı alan 41 adet gastroenteropankreatik nöroendokrin tümör olgusu yaş, cinsiyet, lokalizasyon, çap, mitoz, nekroz, anjiyolenfatik invazyon, perinöral invazyon ve lenf nodu metastazı durumu açısından incelendi. Bulgular: Tümör çapı benign grupta 0,76±0,78 cm olup malign grupta 2,82±2,86 cm olarak saptandı (p=0.006). İyi diferansiye tümör grubu ile iyi diferansiye karsinom grubu arasında mitoz sayısı açısından istatistiksel olarak anlamlı bir farklılık bulunmazken (p>0,05), az diferansiye karsinom grubunda bu parametre diğer gruplardan anlamlı olarak yüksek bulunmuştur(p<0.001). Sonuç: Çalışmamızda tümör çapı açısından benign ve malign gruplar arasında farklılık bulunmakla beraber, çapın her zaman güvenilir bir parametre olmadığı saptanmıştır. Ayrıca yüksek mitozun kötü prognoz ile ilişkili olduğu ancak mitoz sayısının düşük olmasının benign davranışın göstergesi olarak değerlendirilmemesi gerektiğini düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-gastrointestinal-pankreatik-noroendokrin-tumorlerde-prognostik-parametreler.pdf
  • 2
69-73
  • Turkish

REFERENCES

References: 

1-Alexiev BA, Drachenberg CB, Papadimitriou JC. Endocrine
tumors of the gastrointestinal tract and pancreas: Grading,
tumor size and proliferation index do not predict malignant
behavior. Diagn Pathol 2007, 2:28.
2-Modlin IM, Shapiro MD, Kidd M. Siegfried Obendorfer: origins
and perspective of carcinoid tumors. Hum Pathol 2004: 35:1440-
51
3-Grame-Cook F, Neuroendocrine tumors of the gastrointestinal
tract and appendix. In: Odse RD, Goldblum JR. Surgical Pathology
of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd reved.
Philadelphia, 2009: 653-693
4- Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Sitespecific
biology and pathology of gastroenteropancreatic neuroendocrine
tumors. Virchows Arch. 2007;451 Suppl 1:S9-27.
5- Van Gompel JJ, Sippel RS, Warner TF, Chen H. Gastrointestinal
carcinoid tumors: factors that predict outcome. World J Surg.
2004;28:387-92.
6-Rorstad O. prognostic indicators for cardinoid neuroendocrine
tumors of the gastrointestinal tract. J. Surg. Oncol 2005;89:151-
160
7- Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working
Group. Neuroendocrine gastroenteropancreatic tumours:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2010;21 Suppl 5:v223-7.
8-Estrozi B, Bacchi CE. Neuroendocrine tumors involving the
gastroenteropancreatic tract: a clinicopathological evaluation of
773 cases. Clinics(Sau Paulo),2011;66:1671-5
9-Rindi G. The ENETS guidelines: The new TNM classification
system. Tumori 2010;96:806-809
10-Soga J: Early-stage carcinoids of the gastrointestinal tract: An
analysis of 1914 reported cases. Cancer 2005; 103:1587-1595.
11-Xie SD, Vang LB, Song XY, Pan T. Minute gastric carcinoid
tumour with regional lymph node metastasis: a case report and
review of literature. World J Gastroenterol 2004;10:2461-3
12-Kumashiro R, Naitoh H, Teshima K et al. Minute gastric carcinoid
tumor with regional lymph node metastasis. Int Surg
1989;74:198-200
13-Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan
MF, Klimstra DS: Prognostic factors in pancreatic endocrine
neoplasms: An analysis of 136 cases with a proposal for lowgrade
and intermediate-grade groups. J Clin Oncol 2002, 20:2633-2642.
14- Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation
between grade and prognosis in metastatic gastroenteropancreatic
neuroendocrine tumors. Hum Pathol. 2009;40:1262-8.
15-Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas
tumor biology and classification. Neuroendocrinology 2004;1:12-
15
16- Solcia E, Rindi G, Paolotti D, La Rosa S, Capella C, Fiocca R.
Clinicopathological profile as a basis for classification of the
endocrine tumours of the gastroenteropancreatic tract. Ann
Oncol. 1999;10 Suppl 2:S9-15.
17- Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G,
Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S,
Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G.
Prognostic factors and survival in endocrine tumor patients:
comparison between gastrointestinal and pancreatic localization.
Endocr Relat Cancer. 2005;12:1083-92.
18-Solcia E, Kloppel G, Sobin LH (in collaboration with 9 pathologists
from 4 countries). Histological Typing of Endocrine Tumours.
WHO International Histological Classification of Tumours,
2nd ed. Berlin, Germany: Springer;2000
19- Rossi G, Valli R, Bertolini F, Sighinolfi P, Losi L, Cavazza A,
Rivasi F, Luppi G. Does mesoappendix infiltration predict a worse
prognosis in incidental neuroendocrine tumors of the appendix?
A clinicopathologic and immunohistochemical study of 15 cases.
Am J Clin Pathol. 2003;120:706-11.
20- Moertel CG, Dockerty MB, Judd ES. Carcinoid tumurs of the
vermiform appendix.
Carcer 1968;21:270-278

Thank you for copying data from http://www.arastirmax.com